1300019-40-2Relevant articles and documents
THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE
-
, (2022/02/15)
The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo
METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
-
, (2021/08/13)
The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
BET protein inhibitor and applications thereof
-
Paragraph 0049, (2018/04/02)
The present invention relates to a compound represented by a general formula (I) and used for inhibiting BET proteins, particularly BRD4, and uses of the compound in hyperproliferative diseases, mainly in prevention or treatment of tumor diseases, hyperplasia of prostate, inflammatory diseases, autoimmune diseases, sepsis, viral infections, vascular diseases and neurological diseases. The formula(I) is defined in the specification.